Diagnostic Accuracy of 18F-FDG PET/CT in Muscle-invasive Bladder Cancer

Inclusion Criteria: * Adults aged 18 years or older Previously known oncological disease Histologically confirmed diagnosis of high-grade MIBC Non-muscle-invasive, or low-grade bladder cancer Eligible for platinum-based neoadjuvant treatment on clinical evaluation: * ECOG performance status of 0-1, * creatinine clearance of at least 60 mL/min, * absence of comorbidities that would contraindicate chemotherapy (such as grade ≥2 neuropathy, grade ≥2 hearing impairment, or significant cardiopathy) Impossibility to perform imaging procedures, including * Claustrophobia * history of iodinated contrast medium allergy precluding ceCT * diabetes uncontrolled by medications Sign of informed consent Exclusion Criteria: * Adults aged 18 years or older Previously known oncological disease Histologically confirmed diagnosis of high-grade MIBC Non-muscle-invasive, or low-grade bladder cancer Eligible for platinum-based neoadjuvant treatment on clinical evaluation: * ECOG performance status of 0-1, * creatinine clearance of at least 60 mL/min, * absence of comorbidities that would contraindicate chemotherapy (such as grade ≥2 neuropathy, grade ≥2 hearing impairment, or significant cardiopathy) Impossibility to perform imaging procedures, including * Claustrophobia * history of iodinated contrast medium allergy precluding ceCT * diabetes uncontrolled by medications